What can aviation teach us about ADCs and bispecific antibodies?
Blue Angels at Pensacola NAS
The aviation industry is a great example of innovation in practice, both in terms of incremental progress and truly revolutionary breakthroughs over the last few decades.
Think how far we have come since the first flight of an engine-powered heavier-than-air aircraft by the Wright Brothers at Kitty Hawk in December 1903.
Like the pharma industry, aviation is highly regulated and during the design of a new aircraft tradeoffs must be made in terms of the features and benefits, as well as weight, range, and performance.
So what can we learn from the aviation industry when it comes to oncology product development?
Quite a lot actually! I recently spent a morning at the National Naval Aviation museum in Pensacola, Florida and was inspired by what I learned to pen this post.
As an aside – if you are ever in the area, the museum is world class and definitely well worth a visit!
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
